Switching tristetraprolin on to turn off inflammation in COPD

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1141365

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Inflammation drives the pathogenesis of chronic obstructive pulmonary disease (COPD). We have developed a novel anti-inflammatory strategy to treat this currently untreatable disease. Our innovation is to use activators of protein phosphatase 2A to switch the molecule tristetraprolin (TTP) on and repress inflammation in COPD. Switching TTP on to turn off inflammation in COPD has proven potential to prevent irreversible damage and halt the progression of COPD.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2020

Funding Scheme: Project Grants

Funding Amount: $525,390.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Respiratory Diseases

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

RNA binding proteins | anti-inflammatory agents | chronic obstructive pulmonary disease (COPD) | cytokine regulation | inflammation

Related Links